Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain
N. Martinez-Lago, M. Reboredo López, M.C. Riesco Martinez, S. López Peraita et autres
Background: Trifluridine/tipiracil plus bevacizumab (FTD/TPI+BEV) has demonstrated survival benefit in patients with metastatic colorectal cancer (mCRC) after failure of at least two prior treatment regimens in the phase III SUNLIGHT trial (NCT04737187), which compared FTD/TPI+BEV with FTD/TPI monotherapy; however, real-world evidence remains …
es (code pays fourni par la source)
0 citations
ESMO Gastrointestinal Oncology